Document is current
Any future updates will be listed below
-
Authors
Coffey, David G. https://orcid.org/0000-0003-3544-8836
Maura, Francesco https://orcid.org/0000-0002-5017-1620
Gonzalez-Kozlova, Edgar https://orcid.org/0000-0002-6948-0626
Diaz-Mejia, J. Javier https://orcid.org/0000-0003-2475-3077
Luo, Ping https://orcid.org/0000-0002-0039-747X
Zhang, Yong
Xu, Yuexin
Warren, Edus H. https://orcid.org/0000-0002-9570-2755
Dawson, Travis https://orcid.org/0000-0002-9609-793X
Lee, Brian
Xie, Hui
Smith, Eric https://orcid.org/0000-0002-0296-7587
Ciardiello, Amanda
Cho, Hearn J. https://orcid.org/0000-0003-4481-5757
Rahman, Adeeb
Kim-Schulze, Seunghee
Diamond, Benjamin https://orcid.org/0000-0002-8638-9365
Lesokhin, Alexander
Kazandjian, Dickran https://orcid.org/0000-0002-6593-0917
Pugh, Trevor J.
Green, Damian J.
Gnjatic, Sacha https://orcid.org/0000-0001-5643-9520
Landgren, Ola https://orcid.org/0000-0001-6485-4839
-
Funding
Funding for this research was provided by:
Multiple Myeloma Research Foundation (Immune Network of Excellence)
- License Information
-
More Information
Article History
Received: 28 February 2022
Accepted: 18 August 2023
First Online: 2 September 2023
Competing interests
: O.L. acknowledges funding from: NCI/NIH, FDA, LLS, Rising Tide Foundation, Memorial Sloan Kettering Cancer Center, MMRF, IMF, Paula and Rodger Riney Foundation, Perelman Family Foundation, Amgen, Celgene, Janssen, Takeda, Glenmark, Seattle Genetics, Karyopharm; has received honoraria for scientific talks/participated in advisory boards for Adaptive, Amgen, Binding Site, BMS, Celgene, Cellectis, Glenmark, Janssen, Juno, Pfizer; and served on Independent Data Monitoring Committees (IDMC) for international randomized trials by: Takeda, Merck, Janssen, Theradex. S.G. acknowledges funding from U24 CA224319, U01 DK124165, and from the Mount Sinai Tisch Cancer Institute Cancer Center NCI Core Grant P30 CA196521; and reports consultancy and/or advisory roles for Merck and OncoMed; and research funding from Bristol-Myers Squibb, Genentech, Boehringer-Ingelheim, Celgene, Janssen R&D, Pfizer, Takeda, and Regeneron. The remaining authors declare no competing interests.
